Genitourinary

« Previous 123 Next »
Viewing Page 3 of 3 | Showing Results 21 - 24 of 24

A Phase 2 Study of Nivolumab in Combination With Either Rucaparib, Docetaxel, or Enzalutamide in Men With Castration-resistant Metastatic Prostate Cancer

The purpose of this study is to determine which combination of Nivolumab plus either Rucaparib, Docetaxel, or Enzalutamide is the most effective in...

Brendan Curti, M.D.
  • Providence Cancer Institute Franz Clinic

SHS 492453 ZHAS CPFI 18103 - A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

Inclusion Criteria:Histologically or cytologically confirmed adenocarcinoma of the prostate withoutsmall cell or signet cell featuresAsymptomatic...

Song Zhao, M.D.
  • Swedish Medical Center

A Multicentre Phase IIb Trial to Evaluate the Efficacy and Tolerability of ModraDoc006/r in Subjects with Metastatic Castration Resistant Prostate Cancer (mCRPC), Suitable for Treatment with a Taxane

This is a multicenter phase IIb study to evaluate the efficacy and tolerability of ModraDoc006 in combination with ritonavir (denoted...

Brendan Curti, M.D.
  • Oncology and Hematology Care Westside
  • Providence Cancer Institute Clackamas Clinic
  • Providence Cancer Institute Franz Clinic
  • Providence Cancer Institute Newberg Clinic

A Phase 3 Randomized Open Label Study to Compare NKTR-214 Combined with Nivolumab to the Investigator's Choice of Sunitinib or Cabozantinib in Patients with Previously Untreated Advanced Renal Cell Carcinoma

The main purpose of this study is to compare the overall response rate (ORR) and overall survival (OS) of NKTR-214 combined with nivolumab to that...

Brendan Curti, M.D.
  • Providence Cancer Institute Franz Clinic
« Previous 123 Next »
Viewing Page 3 of 3 | Showing Results 21 - 24 of 24